Cancer Research on Prevention and Treatment    2021, Vol. 48 Issue (09) : 859-863     DOI: 10.3971/j.issn.1000-8578.2021.21.0082
|
Association Between Osteogenic Differentiation in Soft Tissue Lump and Clinicopathological Characteristics of Osteosarcoma Patients
WU Zhaoyang1, WANG Shenglin1*, SHEN Rongkai1, CHEN Fei1, LIN Jianhua1, ZHU Xia1, ZHANG Zhenzhen2 (*: Contributed equally as the first author)
1. Department of Orthopaedics, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China; 2. Department of Pathology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China
Download: PDF(8484 KB)   ( 31 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To investigate the association between the osteogenic differentiation in the soft tissue lump and the clinicopathological characteristics of osteosarcoma patients. Methods We retrospectively reviewed the clinical data of conventional osteosarcoma patients with soft tissue lumps, including Enneking stages, chemotherapy sensitivity, overall survival and post-metastatic survival time. The ossification level in soft tissue lumps was assessed by imaging and the proportion of osteoid matrix was assessed by pathological examination. Results A total of 189 cases were included in this study. In patients with Enneking IIIB, nonosteoblastic, partially osteoblastic and osteoblastic types accounted for 30.2%, 9.6% and 6.3%, respectively. Non-osteoblastic osteosarcoma patients had a higher rate of initial metastasis (P<0.05); Chemotherapy efficiency of non-osteoblastic, partially osteoblastic and osteoblastic types were 60.5%, 59.6% and 31.3%, respectively. The osteoblastic osteosarcoma held the worst rate of chemotherapy sensitivity (P<0.05). The overall survival of non-osteoblastic osteosarcoma was shorter than those of partially osteoblastic and osteoblastic types (P<0.05). Post-metastatic survival time of osteoblastic osteosarcoma was longer than that of non-osteoblastic osteosarcoma (P=0.078). Conclusion For conventional osteosarcoma, the osteogenesis level in soft tissue lumps is related to the surgical stage, chemotherapy sensitivity and prognosis of tumors, which may provide guidance for the individual decision regarding chemotherapy and surgery timing on patients.
Keywords Osteosarcoma      Osteogenesis      Chemotherapy      Prognosis     
ZTFLH:  R738.1  
  R738.6  
Fund:Natural Science Foundation of Fujian Province (No. 2018J01168); Funding Plan of Fujian Province Health Middle-aged and Young Backbone Talents Training Project (No. 2019-ZQN-55)
Issue Date: 14 September 2021
 Cite this article:   
?WU Zhaoyang,WANG Shenglin,SHEN Rongkai, et al. Association Between Osteogenic Differentiation in Soft Tissue Lump and Clinicopathological Characteristics of Osteosarcoma Patients[J]. Cancer Research on Prevention and Treatment, 2021, 48(09): 859-863.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2021.21.0082
http://www.zlfzyj.com/EN/Y2021/V48/I09/859
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
?WU Zhaoyang
WANG Shenglin
SHEN Rongkai
CHEN Fei
LIN Jianhua
ZHU Xia
ZHANG Zhenzhen
[1] Hirose K, Okura M, Sato S, et al. Gnathic giant-cell-rich conventional
osteosarcoma with MDM2 and CDK4 gene amplification[J].
Histopathology, 2017, 70(7): 1171-1173.
[2] Scotlandi K, Picci P, Kovar H. Targeted therapies in bone
sarcomas[J]. Curr Cancer Drug Targets, 2009, 9(7): 843-853.
[3] Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic
sarcoma: the rationale for preoperative chemotherapy and delayed
surgery[J]. Cancer, 1979, 43(6): 2163-2177.
[4] Wang SN, Luo S, Liu C, et al. miR-491 Inhibits Osteosarcoma
Lung Metastasis and Chemoresistance by Targeting αBcrystallin[
J]. Mol Ther, 2017, 25(9): 2140-2149.
[5] 马焕, 李振辉, 李鹍, 等. 动态增强MRI定量参数评估骨肉瘤
新辅助化疗疗效价值[J]. 中华肿瘤防治杂志, 2019, 26(6):
421-426. [Ma H, Li ZH, Li K, et al. Quantitative dynamic contrast
enhanced MRI for assessment of osteosarcoma response to neoadjuvant
chemotherapy[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi,
2019, 26(6): 421-426.]
[6] 陈海妹, 刘金, 程梓轩, 等. 基于多中心T1WI影像组学列线图治
疗前预测骨肉瘤一年内复发的价值[J]. 中华放射学杂志, 2020,
54(9): 874-881. [Chen HM, Liu J, Cheng ZX, et al. Value of radiomics
nomogram based on T1WI for pretreatment prediction
of relapse within 1 year in osteosarcoma: a multicenter study[J].
Zhonghua Fang She Xue Za Zhi, 2020, 54(9): 874-881.]
[7] 王国红, 郭直岳, 石松林, 等. 肉桂酸对人骨肉瘤MG-63细胞增
殖和分化的影响[J]. 中国药理学通报, 2012, 28(9): 1262-1266.
[Wang GH, Guo ZY, Shi SL, et al. Effect of cinnamic acid on
proliferation and differentiation of human osteosarcoma MG-63
cells[J]. Zhongguo Yao Li Xue Tong Bao, 2012, 28(9): 1262-1266.]
[8] Ying M, Liu G, Shimada H, et al. Human osteosarcoma CD49f(-)
CD133(+) cells: impaired in osteogenic fate while gain of
tumorigenicity[J]. Oncogene, 2013, 32(36): 4252-4263.
[9] Eliseev RA, Dong YF, Sampson E, et al. Runx2-mediated activation
of the Bax gene increases osteosarcoma cell sensitivity to
apoptosis[J]. Oncogene, 2008, 27(25): 3605-3614.
[10] Hasei J, Sasaki T, Tazawa H, et al. Dual programmed cell death
pathways induced by p53 transactivation overcome resistance to
oncolytic adenovirus in human osteosarcoma cells[J]. Mol Cancer
Ther, 2013, 12(3): 314-325.
[11] 牛晓辉. 中国临床肿瘤学会(CSCO)经典型骨肉瘤诊疗指南
[M]//赫捷, 李进, 马军, 等. 中国临床肿瘤学会(CSCO)常见
恶性肿瘤诊疗指南2020. 北京: 人民卫生出版社, 2020: 454. [Niu
XH. Guidelines of Chinese Society of Clinical Oncology (CSCO)
conventional osteosarcoma[M]//He J, Li J, Ma J, et al. Guidelines
of Chinese Society of Clinical Oncology (CSCO) common malignant
tumor 2020. Beijing: People Health Publishing House, 2020:
454.]
Related articles from Frontiers Journals
[1] LI Jinzhou, WANG Wenjie, YAO Yalong, MU Yanxi, CHEN Kang, SHEN Yimin, WANG Zhou, HUANG Zeping, CHEN Xiao. Development and Validation of Prognostic Nomogram Based on Negative Lymph Node Count for Patients with Gastric Signet Ring Cell Carcinoma#br#[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 923-930.
[2] MAO Wanli, RAN Li, LI Jiehui, LI Fenghu, CHANG Jianying, MU Junyu, MEI Fan, HU Lili, DU Yanjun, TIAN Xue, QIN Yao, YIN Shuishui. Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 937-943.
[3] HUANG Zhenghua, ZHOU Jian, LI Yufu, LIU Yanyan, ZHOU Keshu, SONG Yongping. Clinical Efficacy and Prognostic Factors of Autologous Hematopoietic Stem Cell Transplantation for Hodgkin’s Lymphoma in 38 Cases[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 952-955.
[4] XU XiaoFei, LI Yang, CHEN Lingyun, DAI Heyang, XUE Jiaojiao, LI Qingxia, . Research Progress of PNI and CONUT in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 961-964.
[5] CHEN Zegang, WANG Yongbing, OU Tao. Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 982-986.
[6] JIA Lijuan, ZHANG Yunqiang, ZHANG Baihong, YUE Hongyun. Expression and Clinical Significance of m6A Methylatransferase ZC3H13 in Gastric Cancer Tissues and Serum[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 792-798.
[7] SUI Daxing, WANG Xueying, ZHANG Jiaxin. A New N-staging System for Predicting Postoperative Survival of M0 Stage Inflammatory Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 799-805.
[8] KANG Yikun, YUAN Peng. Advances in Treatment of Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 812-819.
[9] LI Jinzhou, HUANG Zeping, MU Yanxi, YAO Yalong, WANG Wenjie, LIU Haipeng, LIU Jie, WANG Zhou, CHEN Xiao. Prognostic Value of Negative Lymph Nodes Count in Solid Tumors[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 843-849.
[10] ZHOU Silei, SUN Guanqun, ZENG Tanlun, CHENG Zhuo, LIANG Xijun. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
[11] XIA Lili, ZHU Xinyi, ZHANG Xiwei, LI Zhengjiang, LIU Shaoyan, LU Haizhen, AN Changming. Predictive Value of Depth of Invasion of Tongue Squamous Cell Carcinoma for Cervical Lymph Node Metastasis and Prognosis[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 675-681.
[12] WEI Zongjie, KUANG Youlin, CHEN Yong, WANG Lu, CHEN Xiao, GOU Xin. Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 698-702.
[13] WU Wei, JING Doudou, CAO Li, PU Feifei, SHAO Zengwu. Current Status and Prospects of Immunotherapy for Osteosarcoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 721-726.
[14] ZHAN Jianghua, WANG Zhiru, . Progress and Comment on Surgical Treatment of Hepatoblastoma in Children[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 541-545.
[15] . Expression of MAD2L1 in Lung Adenocarcinoma and Its Effect on Immune Microenvironment[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 586-592.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed